SK Capital to exit IBA Molecular

SK Capital said Monday it agree to sell IBA Molecular to CapVest Partners LP. Financial terms weren’t announced. IBA develops, makes and distributes radiopharmaceutical products and supporting services used in molecular imaging with operations throughout Europe and Asia.

14 December 2015•2 mins read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles